
Sign up to save your podcasts
Or
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.
4.7
1414 ratings
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.
494 Listeners
189 Listeners
2,173 Listeners
991 Listeners
1,780 Listeners
279 Listeners
802 Listeners
284 Listeners
179 Listeners
880 Listeners
1,263 Listeners
1,543 Listeners
410 Listeners
41 Listeners
3 Listeners
20 Listeners